Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results